NPI: 1093748071 · MANCHESTER, CT 06042 · 207W00000X
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 23,694 | $2.55M |
| 2019 | 24,822 | $3.15M |
| 2020 | 21,269 | $3.11M |
| 2021 | 34,581 | $3.79M |
| 2022 | 41,499 | $4.16M |
| 2023 | 49,625 | $4.71M |
| 2024 | 48,695 | $4.29M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| J0178 | Aflibercept injection | 36,113 | 20,428 | $18.22M |
| J2777 | Inj, faricimab-svoa, 0.1mg | 4,442 | 2,093 | $2.08M |
| 67028 | 48,227 | 28,891 | $1.55M | |
| J2778 | Ranibizumab injection | 2,750 | 2,183 | $1.33M |
| 92250 | 19,570 | 15,844 | $543K | |
| 92012 | 31,744 | 23,638 | $415K | |
| 92014 | 20,379 | 16,180 | $402K | |
| 92134 | 49,132 | 34,947 | $349K | |
| 67228 | 1,309 | 873 | $157K | |
| 99204 | 3,034 | 2,524 | $154K | |
| J3590 | Unclassified biologics | 311 | 144 | $116K |
| 92235 | 2,922 | 2,444 | $101K | |
| 92226 | 9,427 | 7,342 | $88K | |
| J0177 | Inj, aflibercept hd, 1 mg | 153 | 68 | $73K |
| 99214 | 1,368 | 1,076 | $42K | |
| J9035 | Bevacizumab injection | 914 | 661 | $28K |
| J2781 | Inj, pegcetacoplan, 1mg | 117 | 45 | $26K |
| 92202 | 10,186 | 7,937 | $25K | |
| 67210 | 128 | 102 | $24K | |
| J0179 | Inj, brolucizumab-dbll, 1 mg | 39 | 32 | $13K |
| 99215 | Prolong outpt/office vis | 254 | 206 | $11K |
| 76512 | 136 | 121 | $6K | |
| 92225 | 423 | 352 | $6K | |
| 92020 | 388 | 309 | $3K | |
| 99205 | Prolong outpt/office vis | 52 | 47 | $3K |
| 92201 | 517 | 401 | $1K | |
| 99213 | 104 | 67 | $815.67 | |
| 76510 | 33 | 13 | $667.36 | |
| 99072 | 13 | 13 | $0.00 |